Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient’s response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.

Additional Metadata
Persistent URL dx.doi.org/10.3390/cancers11010093, hdl.handle.net/1765/114992
Journal Cancers
Citation
van der Sijde, F., Vietsch, E.E, Mustafa, D.A.M, Besselink, M.G, Groot Koerkamp, B, & van Eijck, C.H.J. (2019). Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers, 11(1). doi:10.3390/cancers11010093